Log In
BCIQ
Print this Print this
 

IMA300

  Manage Alerts
Collapse Summary General Information
Company immatics biotechnologies GmbH
DescriptionAllogeneic gamma-delta T cell adoptive cell therapies created using immatics' ACTallo platform
Molecular Target
Mechanism of Action 
Therapeutic ModalityCell therapy
Latest Stage of DevelopmentDiscovery
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today